| 3.07 0.02 (0.66%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.75 | 1-year : | 3.91 |
| Resists | First : | 3.21 | Second : | 3.34 |
| Pivot price | 3.2 |
|||
| Supports | First : | 3 | Second : | 2.49 |
| MAs | MA(5) : | 3.11 |
MA(20) : | 3.18 |
| MA(100) : | 3.27 |
MA(250) : | 4.11 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 20.3 |
D(3) : | 30.8 |
| RSI | RSI(14): 42.8  |
|||
| 52-week | High : | 12.14 | Low : | 2.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EVAX ] has closed above bottom band by 6.0%. Bollinger Bands are 42.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.13 - 3.15 | 3.15 - 3.17 |
| Low: | 2.97 - 3 | 3 - 3.02 |
| Close: | 3.04 - 3.07 | 3.07 - 3.1 |
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Sat, 05 Sep 2026
Evaxion Biotech Boosts Share Capital With August 2026 ATM ADS Offering - The Globe and Mail
Thu, 20 Aug 2026
Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery? - Yahoo Finance
Sun, 26 Jul 2026
Evaxion Biotech A/S (EVAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Thu, 25 Jun 2026
EVAX Forecast — Price Target — Prediction for 2027 - TradingView
Mon, 26 May 2025
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 (NASDAQ:EVAX) - Seeking Alpha
Fri, 16 May 2025
Evaxion (Nasdaq:EVAX) - Stock Analysis - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 16.1 (%) |
| Held by Institutions | 9.4 (%) |
| Shares Short | 51 (K) |
| Shares Short P.Month | 57 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.13 |
| Profit Margin | -115.6 % |
| Operating Margin | -116.1 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -109.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.83 |
| Sales Per Share | 0.83 |
| EBITDA (p.s.) | -0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -3.07 |
| PEG Ratio | 0 |
| Price to Book value | 2.69 |
| Price to Sales | 3.69 |
| Price to Cash Flow | -3.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|